Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Pharmaceuticals · 19.04.2023 · 16 (4) · 614
DOI: 10.3390/ph16040614 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 19.04.2023. Verfasst von Valentina Tateo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies are FDA-approved. (2)
Methods
We performed a review of the literature and reported the trials that led to the approval of tissue-agnostic treatments and ongoing clinical trials currently investigating novel biomarker-based approaches. (3)
Results
We discussed the approval of agnostic treatments: pembrolizumab and dostarlimab for MMRd/MSI-H, pembrolizumab for TMB-H, larotrectinib and entrectinib for NTRK-fusions, dabrafenib plus trametinib for BRAF V600E mutation, and selpercatinib for RET fusions. In addition, we reported novel clinical trials of biomarker-based approaches, including ALK, HER2, FGFR, and NRG1. (4)
Conclusions
Precision medicine is constantly evolving, and with the improvement of diagnostic tools that allow a wider genomic definition of the tumor, tissue-agnostic targeted therapies are a promising treatment strategy tailored to the specific tumor genomic profile, leading to improved survival outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40127 Bologna, Italy.
- MCW Cancer Center, Milwaukee, WI 53226, USA.
- WIN Consortium, San Diego, CA 92093, USA.
- Department of Oncology, University of Nebraska, Omaha, NE 68198, USA.
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD 21287, USA.
ORCID-Profile: Valentina Tateo, Veronica Mollica, Francesco Massari, Jacob J Adashek
Zitieren
APA
Tateo, V., Marchese, P. V., Mollica, V., Massari, F., Kurzrock, R., & Adashek, J. J. (2023). Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals, 16(4), 614. https://doi.org/10.3390/ph16040614
Vancouver
Tateo V, Marchese PV, Mollica V, Massari F, Kurzrock R, Adashek JJ. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals. 2023;16(4):614. doi:10.3390/ph16040614
BibTeX
@article{Tateo2023,
author = {Tateo, Valentina and Marchese, Paola Valeria and Mollica, Veronica and Massari, Francesco and Kurzrock, Razelle and Adashek, Jacob J},
title = {Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {4},
pages = {614},
doi = {10.3390/ph16040614}
}
EUVIMED